Amgen’s PCSK9 inhibitor Repatha “significantly” reduced the risk of cardiovascular events — heart attacks, strokes, and the like — compared to placebo. Investors will have to wait until the American College of Cardiology meeting next month to find out how significant the reduction was.
Category: Alnylam Pharmaceuticals
Here’s Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
That was a far worse decline than the 19% loss by the biotech sector, in general, as measured by the iShares Nasdaq Biotechnology ETF While Alnylam’s share price was weak through the first nine months of the year, investors can mostly chalk that up to the general sell-off in biotech. However, the company’s stock was decimated in October after the company reported a major clinical setback.
Why Cliffs Natural Resources, Groupon, and Alnylam Pharmaceuticals Slumped Today
Thursday was another sluggish day on Wall Street, with the Dow once again moving away from the 20,000 mark rather than toward it. Most major market benchmarks were down slightly on the day, as investors seemed content to coast into the end of the year as they wait to see whether things in 2017 will go as well as the recent stock market rally would suggest.